Twelve-year follow-up study of hepatitis B immunization of Senegalese infants.
Numerous studies have documented the efficacy and safety of plasma-derived and recombinant hepatitis B vaccines. However, little is known about the long-term protection of hepatitis B vaccine, when anti-HBs declines to low or undetectable levels. This study reports results from a 9-12-year period follow up of infants immunized against hepatitis B in Senegal. At the end of the follow-up period anti-HBs were detected in 81% of children who received a booster dose at school age and in 68% of those who did not. HBsAg was detected in 19% of infants from the control group compared to only 2% of immunized infants, corresponding to a protective efficacy of 88%. The results show that long-term protection against HBsAg carriage of hepatitis B vaccination is very high and that a booster dose at school age does not significantly increase this protection.
Coursaget
P
P
Institut de Virologie de Tours, Faculté de Pharmacie, Tours France.
Leboulleux
D
D
Soumare
M
M
le Cann
P
P
Yvonnet
B
B
Chiron
J P
JP
Coll-Seck
A M
AM
Diop-Mar
I
I
D002648:Child; D002675:Child, Preschool; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000453:epidemiology* / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000032:analysis / Q000097:blood; D017325:Hepatitis B Vaccines / Q000009:adverse effects / Q000592:standards*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D012675:Senegal / Q000453:epidemiology
D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines